Fulcrum Therapeutics move lower ‘overdone,’ says Stifel

3 weeks ago 17

TipRanks

Wed, February 25, 2026 astatine 9:27 AM CST 1 min read

Stifel expert James Condulis tells investors that the determination little successful Fulcrum Therapeutics (FULC) this greeting “surprises us” and looks “overdone.” While the steadfast believes immoderate thought full mean HbF whitethorn comfortably beryllium greater than 20% fixed the spot of the archetypal chopped astatine ASH, the steadfast thinks “overly nitpicking 19.3% is splitting hairs and misses the bigger picture” arsenic these information surpassed the doc “bar” and that pociredir is reaching HbF levels expected to beryllium highly protective of disease. Even with a rebound this morning, shares importantly discount a soon-to-be late-stage plus with a validated mechanics of enactment successful the white-space sickle compartment illness market, argues the analyst, who has a Buy standing and $25 price target connected Fulcrum shares.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected FULC:

Disclaimer & DisclosureReport an Issue

Truist stay buyers of Fulcrum Therapeutics shares connected weakness
Fulcrum Therapeutics announces results from Phase 1b PIONEER proceedings of pociredir
Fulcrum Therapeutics reports Q4 EPS (31c), statement (30c)
Fulcrum Therapeutics (FULC) Q4 Earnings Cheat Sheet
Pociredir’s Emerging Strength successful Sickle Cell Disease Positions FULC for Upside Ahead of 1Q26 Data

Read Entire Article